# The Opioid Crisis: Political Perspectives Analysis

## Overview

This document analyzes the opioid crisis through nine distinct political perspectives, evaluating current state assessments, root cause analyses, proposed solutions, and legislation. Each perspective receives engagement consistency ratings and position scores, culminating in compromise proposals that bridge multiple viewpoints. The opioid crisis is notable for generating more bipartisan agreement than most policy domains, though significant divisions remain on harm reduction, decriminalization, industry accountability, and the balance between public health and law enforcement approaches.

## Perspective Definitions

| Perspective | Core Values | Policy Orientation |
|-------------|-------------|-------------------|
| Conservative | Tradition, limited government, individual responsibility | Incremental change, fiscal restraint, market solutions |
| Liberal | Progress, equality, social responsibility | Government as problem-solver, regulation, safety nets |
| Progressive | Systemic change, economic justice, structural reform | Transformative reform, wealth redistribution, worker power |
| Libertarian | Individual liberty, minimal state, free markets | Deregulation, privatization, voluntary association |
| Constitutionalist | Original intent, enumerated powers, federalism | Strict constitutional limits, states' rights |
| Populist | Anti-elite, pro-worker, economic nationalism | Trade protection, anti-monopoly, immigration restriction |
| Centrist | Pragmatism, compromise, incremental progress | Bipartisan solutions, evidence-based policy |
| Religious Right | Faith-based values, traditional morality | Social conservatism, religious liberty |
| Democratic Socialist | Worker ownership, public goods, democratic control | Public investment, labor rights, universal programs |

## Scoring Framework

### Position Scores (1-10)

| Score | Meaning |
|-------|---------|
| 10 | Full agreement with project analysis |
| 7-9 | Substantial to strong agreement |
| 5-6 | Mixed/moderate agreement |
| 3-4 | Substantial disagreement |
| 1-2 | Strong opposition |

### Engagement Consistency (1-5)

| Level | Label | Indicators |
|-------|-------|------------|
| 5 | Highly Consistent | Stated positions reflect underlying principles; positions stable when concerns addressed |
| 4 | Mostly Consistent | Principles generally align with positions; minor strategic flexibility |
| 3 | Mixed Consistency | Some positions principled, others reflect coalition pressures or unstated concerns |
| 2 | Low Consistency | Positions shift frequently; stated concerns differ from underlying priorities |
| 1 | Unpredictable | Positions appear driven primarily by opposition dynamics rather than principles |

### Legislation Status Reference (as of January 2025)

| Bill/Amendment | Type | Current Status | Last Action |
|----------------|------|----------------|-------------|
| OCRAA (proposed) | Federal | Proposed | Draft in this analysis |
| MAT Access Act (proposed) | Federal | Proposed | Draft in this analysis |
| Naloxone for All Act (proposed) | Federal | Proposed | Draft in this analysis |
| SUPPORT Act | Federal | Enacted (2018) | Implementation ongoing |
| X-waiver elimination | Federal | Enacted (2023) | Implemented |

*Note: See [11-legislation.md](11-legislation.md) for full bill text.*

---

## Perspective Analyses

### Conservative Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Stated concern for individual responsibility is genuine but applied inconsistently; pharmaceutical industry accountability often de-emphasized relative to user accountability |
| Principle consistency | Limited government principle conflicts with support for aggressive enforcement; personal responsibility principle conflicts with sympathy for affected (often white, rural) communities |
| Goalpost stability | Positions have shifted significantly since 2015 as the crisis affected core constituencies; enforcement emphasis has softened |
| Zero-sum behavior | Moderate; willing to support treatment funding but resistant to harm reduction framing |

**Justification:** Conservative positions on the opioid crisis have evolved substantially as the crisis has disproportionately affected rural, white, working-class communities that form a core constituency. The shift from "personal responsibility" to "these are our neighbors" reflects genuine empathy but also political calculation, creating mixed consistency.

**Evidence for assessment:**

- The SUPPORT Act (2018) received broad Republican support, representing a significant shift from enforcement-only approaches
- Republican governors in states like Ohio, West Virginia, and Kentucky have been among the most aggressive in pursuing treatment expansion
- However, conservative opposition to harm reduction (SSPs, SCS) and resistance to pharmaceutical industry accountability have limited the scope of response
- Heritage Foundation positions have shifted from emphasizing enforcement to acknowledging treatment needs, while maintaining opposition to harm reduction

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | Generally accepts the severity of the crisis; may underweight systemic causes relative to individual choices |
| Root Cause Agreement | 5/10 | Accepts pharmaceutical industry misconduct but also emphasizes personal responsibility and border security; underweights economic despair analysis |

**Source references:**

- Heritage Foundation, "Solutions to the Opioid Crisis" (2018)
- American Enterprise Institute, "Fighting the Opioid Crisis" (2019)
- Republican Congressional opioid caucus positions

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 6/10 | Supports treatment but prefers abstinence options | Philosophical preference for abstinence; concern about long-term medication dependence |
| Universal naloxone | 7/10 | Supports as life-saving measure | Bipartisan consensus has reduced resistance; some moral hazard concerns persist |
| Harm reduction (SSPs, SCS) | 3/10 | Opposes as enabling drug use | Cultural opposition to "facilitating" drug use; NIMBY concerns; moral framework |
| Industry accountability | 4/10 | Accepts existing settlements; opposes further regulation | Business-friendly orientation; concern about litigation culture |
| Prevention | 7/10 | Supports, especially family and community-based | Aligned with traditional values framework |
| Enforcement/border security | 8/10 | Strongly supports supply-side enforcement | Core security and sovereignty values |
| Workforce development | 6/10 | Supports if market-oriented | Prefers private sector solutions to government programs |
| Settlement fund oversight | 6/10 | Supports oversight but opposes federal mandates on state funds | Federalism concerns |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 4/10 | Opposes SCS provisions, revolving door restrictions; supports settlement oversight concept | Government overreach; harm reduction opposition; business regulation concerns |
| MAT Access Act | 5/10 | Mixed; supports telehealth and some reform; concerns about methadone expansion | Diversion risk; correctional cost mandates; federal overreach into state corrections |
| Naloxone for All Act | 6/10 | Supports naloxone access; opposes price controls and compulsory licensing | Free market principles; government price controls |

#### Alternative Proposals

- Emphasize faith-based recovery programs alongside clinical treatment
- Prioritize border security and fentanyl interdiction with increased CBP/DEA resources
- Support drug courts and court-mandated treatment rather than decriminalization
- Use tax incentives rather than mandates to encourage employer-based recovery support
- Maintain state flexibility in settlement fund allocation rather than federal oversight mandates

#### Coalition Potential

- **Natural allies:** Populist (on industry accountability, border security), Religious Right (on faith-based recovery, prevention)
- **Potential bridges:** Centrist (on treatment expansion, evidence-based approaches), Liberal (on MAT access, naloxone)
- **Unlikely partners:** Progressive (on systemic reform framing), Democratic Socialist (on public spending levels, government role)

---

### Liberal Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to treatment expansion and public health approach; aligns with broader healthcare reform priorities |
| Principle consistency | Government problem-solving principle consistently applied; support for regulation, coverage expansion, and accountability |
| Goalpost stability | Positions have been relatively stable; increasingly supportive of harm reduction |
| Zero-sum behavior | Low; generally willing to support multiple approaches simultaneously |

**Justification:** The liberal perspective has been largely consistent in framing the opioid crisis as a public health issue requiring government intervention, treatment expansion, and industry accountability. Positions have been stable and principled, with the main tension being between harm reduction supporters and more cautious moderates within the perspective.

**Evidence for assessment:**

- Democratic leadership supported the SUPPORT Act and has consistently advocated for increased treatment funding
- ACA Medicaid expansion has been strongly associated with improved OUD treatment access in states that adopted it
- Liberal organizations have increasingly endorsed harm reduction, though with some internal division on SCS
- Senate Democrats led pharmaceutical industry investigations and accountability efforts

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Strong agreement with the data and analysis; accepts the crisis as a systemic failure |
| Root Cause Agreement | 8/10 | Strong agreement on industry misconduct and regulatory failure; generally accepts economic despair analysis; may underweight enforcement-related causes |

**Source references:**

- Center for American Progress, "Addressing the Opioid Epidemic" (2020)
- Democratic Party platforms, 2016-2024
- Senate HELP Committee reports on pharmaceutical industry practices

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 9/10 | Strongly supports; led X-waiver elimination effort | Want broader healthcare system reform as well |
| Universal naloxone | 9/10 | Strongly supports; led OTC approval effort | Concerned about pricing access |
| Harm reduction (SSPs, SCS) | 8/10 | Supports SSPs; mixed on SCS (growing support) | Some moderates cautious about political risks of SCS |
| Industry accountability | 9/10 | Strongly supports; favors criminal liability for executives | Want stronger accountability than settlements alone |
| Prevention | 8/10 | Supports comprehensive prevention including social determinants | Prefers government-led programs |
| Enforcement/border security | 5/10 | Supports targeted enforcement; opposes mass incarceration approach | Concerned about racial disparities; prefers demand reduction |
| Workforce development | 8/10 | Strongly supports government investment | Prefers public funding over market approaches |
| Settlement fund oversight | 9/10 | Strongly supports independent oversight and evidence-based allocation | Diversion of tobacco settlement funds is cautionary precedent |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 8/10 | Supports most provisions; would strengthen some | Want larger appropriations; broader SCS authorization |
| MAT Access Act | 9/10 | Strongly supports methadone reform and criminal justice MAT | Want to ensure equity in implementation |
| Naloxone for All Act | 9/10 | Strongly supports; may want stronger price controls | Concerned about pharmaceutical pricing power |

#### Alternative Proposals

- Integrate opioid response into broader universal healthcare reform
- Strengthen racial equity requirements in all programs
- Increase appropriation levels beyond proposed amounts
- Expand safe consumption site authorization beyond pilot
- Mandate comprehensive insurance coverage for all substance use disorder treatments

#### Coalition Potential

- **Natural allies:** Progressive (on systemic reform, accountability), Democratic Socialist (on public investment, universal programs)
- **Potential bridges:** Centrist (on evidence-based approaches), Conservative (on treatment funding, naloxone)
- **Unlikely partners:** Libertarian (on government role), Constitutionalist (on federal authority)

---

### Progressive Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to structural reform and corporate accountability; positions align with broader economic justice agenda |
| Principle consistency | Consistently applies systemic analysis; treats opioid crisis as example of broader capitalist failures |
| Goalpost stability | Stable positions with clear direction toward more comprehensive reform |
| Zero-sum behavior | Low; seeks transformative solutions rather than tactical wins |

**Justification:** The progressive perspective has been consistently principled in framing the opioid crisis as a result of corporate greed, regulatory capture, and economic inequality. Positions are stable and coherent within the broader progressive framework.

**Evidence for assessment:**

- Sen. Sanders and progressive caucus members have consistently pushed for stronger pharmaceutical accountability
- Progressive organizations have led calls for decriminalization and comprehensive harm reduction
- Progressive economic analysis of "deaths of despair" aligns with Case and Deaton framework
- Consistent support for universal treatment access and elimination of stigma

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Strong agreement with crisis severity and systemic analysis |
| Root Cause Agreement | 9/10 | Strong agreement on corporate deception, regulatory capture, and economic despair; may emphasize structural causes even more than the analysis |

**Source references:**

- Sanders Institute policy papers on pharmaceutical accountability
- People's Policy Project analysis of opioid crisis
- Physicians for a National Health Program position statements

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 9/10 | Strongly supports within universal healthcare framework | Prefers public system delivery |
| Universal naloxone | 9/10 | Strongly supports; would go further on pricing | Oppose pharmaceutical profit from crisis they created |
| Harm reduction (SSPs, SCS) | 10/10 | Strongest supporter of comprehensive harm reduction | See harm reduction as structural justice issue |
| Industry accountability | 10/10 | Supports criminal prosecution of executives; settlements insufficient | Want systemic restructuring of pharmaceutical industry |
| Prevention | 9/10 | Supports, with emphasis on economic determinants | Connect prevention to broader anti-poverty agenda |
| Enforcement/border security | 3/10 | Opposes criminalization of drug use; supports decriminalization | See enforcement as perpetuating racial injustice |
| Workforce development | 8/10 | Supports with emphasis on public sector, living wages | Oppose reliance on private sector |
| Settlement fund oversight | 9/10 | Strongly supports community control of funds | Want affected communities to direct spending |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 7/10 | Supports but wants stronger provisions | Appropriations insufficient; SCS pilot too limited; accountability too weak |
| MAT Access Act | 8/10 | Strongly supports | Would embed in universal healthcare |
| Naloxone for All Act | 8/10 | Supports; wants public manufacturing option | Opposed to pharmaceutical industry profiting from crisis response |

#### Alternative Proposals

- Public manufacture of naloxone and generic buprenorphine
- Full drug decriminalization modeled on Portugal
- Criminal prosecution of Sackler family members and other executives
- Universal healthcare with integrated addiction treatment
- Federal jobs program for communities devastated by the crisis

#### Coalition Potential

- **Natural allies:** Democratic Socialist (on public ownership, universal programs), Liberal (on accountability, treatment)
- **Potential bridges:** Populist (on corporate accountability, anti-elite sentiment)
- **Unlikely partners:** Conservative (on government role), Libertarian (on regulation), Religious Right (on harm reduction)

---

### Libertarian Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to individual liberty and limited government; consistently applied to both drug use and regulation |
| Principle consistency | High internal consistency: opposes both drug prohibition and government regulation of pharmaceutical industry |
| Goalpost stability | Positions stable; libertarians have long advocated drug decriminalization |
| Zero-sum behavior | Low; principled framework applied consistently |

**Justification:** The libertarian perspective has the most internally consistent position on drug policy: individual adults should be free to make their own choices about substance use, and government intervention (whether prohibition or regulatory mandates) generally causes more harm than it prevents. This consistency extends to opposing both the War on Drugs and heavy-handed pharmaceutical regulation.

**Evidence for assessment:**

- Cato Institute has consistently advocated for drug decriminalization
- Libertarian Party platform supports ending the War on Drugs
- Reason Foundation has published extensively on harm reduction and treatment access
- Consistent opposition to both enforcement and regulatory expansion

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | Accepts the severity of the crisis; frames it differently (as consequence of prohibition and regulation, not market failure) |
| Root Cause Agreement | 5/10 | Agrees on regulatory failure and FDA capture but disagrees on solutions; sees government as the problem, not insufficient regulation |

**Source references:**

- Cato Institute, "Rethinking the War on Drugs" (2021)
- Reason Foundation opioid policy research
- Libertarian Party platform on drug policy

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 7/10 | Supports removing regulatory barriers; opposes government mandates | Supports deregulation, not new government programs |
| Universal naloxone | 6/10 | Supports access but opposes government distribution programs | Prefers market solutions and private charity |
| Harm reduction (SSPs, SCS) | 7/10 | Supports as alternatives to prohibition; opposes government funding | Principled support for individual choice; opposes taxpayer funding |
| Industry accountability | 4/10 | Supports fraud prosecution but opposes broad regulation | Distinguishes between fraud (punishable) and regulation (undesirable) |
| Prevention | 5/10 | Skeptical of government prevention programs | Prefers family and community over government |
| Enforcement/border security | 2/10 | Strongly opposes drug prohibition and the War on Drugs | Core libertarian principle: individual sovereignty over own body |
| Workforce development | 4/10 | Opposes government workforce programs; supports deregulation | Removing barriers is preferable to creating programs |
| Settlement fund oversight | 3/10 | Skeptical of government ability to manage funds effectively | Government oversight creates bureaucracy without improving outcomes |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 3/10 | Opposes new federal programs and mandates; supports deregulation elements | Government expansion, spending, regulatory authority |
| MAT Access Act | 5/10 | Supports methadone deregulation; opposes mandates on correctional facilities and insurers | Mandates on private businesses and state/local governments |
| Naloxone for All Act | 3/10 | Opposes government distribution program and price controls | Government intervention in markets; compulsory licensing |

#### Alternative Proposals

- Decriminalize all drugs and end the War on Drugs
- Deregulate methadone and buprenorphine without creating new government programs
- Allow pharmaceutical competition through reduced FDA barriers
- Rely on private charity, mutual aid, and community organizations for treatment
- Hold pharmaceutical executives criminally liable for fraud while opposing industry-wide regulation

#### Coalition Potential

- **Natural allies:** None fully aligned on both deregulation and decriminalization
- **Potential bridges:** Progressive (on decriminalization, harm reduction), Conservative (on limited government, deregulation)
- **Unlikely partners:** Populist (on regulation), Religious Right (on drug use morality), Democratic Socialist (on government programs)

---

### Constitutionalist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to federalism and enumerated powers; applied consistently to drug policy |
| Principle consistency | Consistently favors state authority over federal mandates; skeptical of federal spending programs |
| Goalpost stability | Stable positions rooted in constitutional interpretation |
| Zero-sum behavior | Moderate; willing to support action at state level that would oppose at federal level |

**Justification:** Constitutionalists apply federalism principles consistently to opioid policy, preferring state-level solutions and opposing federal mandates. The perspective is internally coherent but can appear resistant to action because of process objections.

**Evidence for assessment:**

- Federalist Society publications on drug policy and federal authority
- State-rights arguments applied consistently across policy domains
- Support for state-level innovation (drug courts, PDMP programs) while opposing federal mandates

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 6/10 | Accepts the crisis is real; concerned about federal overreach in response |
| Root Cause Agreement | 5/10 | Accepts regulatory failure but focuses on federal government overreach as a root cause rather than insufficient regulation |

**Source references:**

- Federalist Society drug policy publications
- Tenth Amendment Center positions on drug policy
- Constitutional commentary on Commerce Clause limits

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 5/10 | Supports at state level; opposes federal mandates | Federal mandates on states violate federalism |
| Universal naloxone | 5/10 | Supports state-level access; opposes federal program | Not a legitimate federal function |
| Harm reduction | 4/10 | State decision; opposes federal authorization or funding | Federal overreach into state police power |
| Industry accountability | 5/10 | Supports state AG litigation; skeptical of federal intervention | State tort law is the appropriate mechanism |
| Prevention | 5/10 | Supports at state and local level | Education and health are state responsibilities |
| Enforcement | 4/10 | Questions constitutional basis for federal drug prohibition | Controlled Substances Act may exceed Commerce Clause |
| Workforce development | 4/10 | State responsibility | Federal education mandates exceed authority |
| Settlement fund oversight | 3/10 | States should manage their own funds without federal conditions | Federal conditions on state funds violate sovereignty |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 3/10 | Opposes federal mandates on states; questions constitutional authority | Exceeds enumerated powers; violates Tenth Amendment |
| MAT Access Act | 4/10 | Supports deregulation of methadone; opposes mandates on state corrections | Unfunded mandates; federal overreach into state criminal justice |
| Naloxone for All Act | 3/10 | Opposes federal distribution program | Not an enumerated federal power |

#### Alternative Proposals

- Repeal federal drug scheduling for substances without interstate commerce nexus
- Support state-level experimentation with diverse approaches
- Use block grants with minimal federal conditions rather than prescriptive programs
- Rely on state tort systems for pharmaceutical accountability
- Constitutional amendment process for any fundamental drug policy reform

#### Coalition Potential

- **Natural allies:** Libertarian (on limited government), Conservative (on federalism)
- **Potential bridges:** Populist (on anti-federal sentiment)
- **Unlikely partners:** Progressive (on federal programs), Liberal (on federal mandates), Democratic Socialist (on government expansion)

---

### Populist Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine anger at pharmaceutical industry and elites; mixed application of anti-elite principle |
| Principle consistency | Anti-elite principle applied to pharma but not consistently to all corporate actors; border security emphasis reflects broader agenda |
| Goalpost stability | Positions shift based on political dynamics and which elites are targeted |
| Zero-sum behavior | Moderate; views crisis through us-vs-them lens |

**Justification:** The populist perspective combines genuine outrage at pharmaceutical industry exploitation of working-class communities with broader political agendas (border security, anti-elite sentiment) that do not always align with evidence-based crisis response. The anti-corporate sentiment is genuine but selectively applied.

**Evidence for assessment:**

- Strong populist support for pharmaceutical industry lawsuits and accountability
- Border security framing of fentanyl crisis aligns with broader immigration agenda
- Skepticism of "elite" solutions (harm reduction, decriminalization) perceived as disconnected from working-class communities
- Support for treatment programs that serve "ordinary Americans" affected by the crisis

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | Strongly agrees the crisis is devastating working-class communities; may overemphasize border dimension |
| Root Cause Agreement | 6/10 | Strong agreement on corporate malfeasance; adds emphasis on border security and Chinese precursor chemicals; may underweight domestic systemic factors |

**Source references:**

- Trump administration ONDCP positions (2017-2021)
- Populist commentary from figures like J.D. Vance (pre-Senate)
- Working-class community advocacy organizations in Appalachia and Rust Belt

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 6/10 | Supports treatment for affected communities | Skeptical of medication-based approaches; prefers "real recovery" |
| Universal naloxone | 7/10 | Supports as life-saving for working-class families | Crisis affects core constituency |
| Harm reduction | 3/10 | Skeptical; views as elite-driven policy disconnected from communities | Cultural resistance; association with urban progressive politics |
| Industry accountability | 9/10 | Strongly supports; wants criminal prosecution of pharma executives | Anti-elite anger; justice for exploited communities |
| Prevention | 7/10 | Supports community-based prevention | Aligned with protecting families and communities |
| Enforcement/border security | 9/10 | Strongly supports fentanyl interdiction and border enforcement | Core security issue; connects to immigration agenda |
| Workforce development | 6/10 | Supports if focused on affected communities | Skeptical of programs that benefit "elites" |
| Settlement fund oversight | 7/10 | Supports ensuring funds reach affected communities | Concern that elites and bureaucrats will capture funds |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 5/10 | Supports accountability and settlement oversight; opposes harm reduction provisions | SCS and SSP provisions; insufficient border focus |
| MAT Access Act | 5/10 | Mixed; supports treatment access but prefers abstinence-oriented models | Methadone expansion seen as "replacing one drug with another" |
| Naloxone for All Act | 7/10 | Supports as community life-saving measure | Cost concerns secondary to saving working-class lives |

#### Alternative Proposals

- Massively increase border enforcement and fentanyl interdiction
- Criminal prosecution of Sackler family members
- Community-based treatment programs run by and for affected communities
- Tariffs or sanctions on Chinese precursor chemical manufacturers
- Death penalty for major fentanyl traffickers

#### Coalition Potential

- **Natural allies:** Conservative (on enforcement, border security), Religious Right (on community values)
- **Potential bridges:** Progressive (on corporate accountability), Liberal (on treatment funding)
- **Unlikely partners:** Libertarian (on enforcement), Constitutionalist (on federal action)

---

### Centrist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to evidence-based, bipartisan solutions; pragmatism is the principle |
| Principle consistency | Consistently applies evidence and pragmatism criteria; willing to adopt solutions from across the spectrum |
| Goalpost stability | Stable; anchored to evidence and feasibility |
| Zero-sum behavior | Very low; actively seeks compromise and broad coalition |

**Justification:** The centrist perspective has been the most consistent bridge-builder on opioid policy, supporting the bipartisan SUPPORT Act, evidence-based treatment expansion, and pragmatic harm reduction. Positions are anchored to evidence and political feasibility rather than ideology.

**Evidence for assessment:**

- Bipartisan Policy Center opioid recommendations reflect centrist synthesis
- Centrist senators (e.g., Capito, Hassan, Manchin, Collins) led bipartisan opioid legislation
- Support for evidence-based approaches regardless of ideological origin
- Willingness to support harm reduction when evidence is strong

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Strong agreement with data-driven analysis |
| Root Cause Agreement | 8/10 | Accepts multi-causal analysis; may balance industry and individual responsibility more equally |

**Source references:**

- Bipartisan Policy Center, "Combating the Opioid Crisis" (2019)
- Third Way drug policy positions
- Bipartisan Senate opioid caucus positions

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 9/10 | Strongly supports as evidence-based | Wants implementation to be practical and sustainable |
| Universal naloxone | 9/10 | Strongly supports | Clear evidence, bipartisan support |
| Harm reduction | 6/10 | Supports SSPs based on evidence; cautious on SCS | Wants to maintain broad coalition; SCS is politically divisive |
| Industry accountability | 7/10 | Supports existing settlements and oversight | Prefers negotiated solutions over punitive approaches |
| Prevention | 8/10 | Strongly supports evidence-based prevention | Prefers proven programs over experimental approaches |
| Enforcement | 6/10 | Supports balanced enforcement and treatment | Wants both supply and demand reduction |
| Workforce development | 8/10 | Supports bipartisan investment | Practical implementation focus |
| Settlement fund oversight | 8/10 | Strongly supports transparent, evidence-based allocation | Key centrist priority |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 6/10 | Supports many provisions; concerned about SCS and spending levels | Political feasibility; bipartisan passage potential |
| MAT Access Act | 8/10 | Strongly supports; model for bipartisan legislation | Implementation timeline realism |
| Naloxone for All Act | 8/10 | Strongly supports; may prefer market mechanisms for pricing | Price control provisions may reduce bipartisan appeal |

#### Alternative Proposals

- Build on the SUPPORT Act framework with incremental expansions
- Pursue bipartisan settlement fund oversight legislation
- Invest in evidence-based treatment without controversial harm reduction provisions
- Support public-private partnerships for workforce development
- Gradual, evidence-driven expansion of harm reduction based on pilot results

#### Coalition Potential

- **Natural allies:** Liberal (on treatment, evidence), Conservative (on pragmatic approaches)
- **Potential bridges:** All perspectives on shared priorities (naloxone, treatment, accountability)
- **Unlikely partners:** Extremes on either side that reject compromise

---

### Religious Right Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine compassion for affected individuals combined with moral framework that complicates harm reduction |
| Principle consistency | Compassion and moral responsibility principles sometimes conflict; opposition to harm reduction may prioritize moral messaging over life-saving |
| Goalpost stability | Evolving; many faith communities have become more supportive of treatment as the crisis has affected congregations |
| Zero-sum behavior | Moderate; frames some solutions as moral capitulation |

**Justification:** The religious right has been significantly affected by the opioid crisis, which has devastated many evangelical and Catholic communities. This has created genuine tension between moral frameworks that view drug use as sin and compassionate response to suffering. Some faith leaders have moved substantially toward treatment support, while others maintain abstinence-only positions.

**Evidence for assessment:**

- Evangelical community organizations have increasingly supported treatment programs
- Southern Baptist Ethics and Religious Liberty Commission has acknowledged the crisis's impact on churches
- Faith-based recovery programs (e.g., Celebrate Recovery, Teen Challenge) serve hundreds of thousands
- Ongoing resistance to harm reduction framing and SSPs

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | Accepts the crisis's severity; frames through spiritual and moral lens in addition to public health |
| Root Cause Agreement | 5/10 | Accepts corporate misconduct but adds moral and spiritual dimensions (family breakdown, loss of faith, cultural decline) that the analysis does not emphasize |

**Source references:**

- Ethics and Religious Liberty Commission (ERLC) opioid positions
- National Association of Evangelicals statements on addiction
- Catholic social teaching on addiction and public health
- Celebrate Recovery and faith-based treatment program advocacy

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 5/10 | Supports treatment access; many prefer faith-based and abstinence approaches | Theological framework values complete freedom from substances |
| Universal naloxone | 7/10 | Supports as life-saving; "every life is sacred" | Pro-life principle applied to overdose prevention |
| Harm reduction | 2/10 | Strongly opposes SSPs and SCS as enabling sin | Moral framework views facilitating drug use as complicity |
| Industry accountability | 6/10 | Supports accountability for deception | Moderate; not a primary focus |
| Prevention | 9/10 | Strongly supports, especially family and youth-focused | Aligned with protecting families and children |
| Enforcement | 7/10 | Supports targeting traffickers; compassionate toward users | Distinguishes between dealers (punishment) and users (compassion) |
| Workforce development | 6/10 | Supports if includes faith-based providers | Want recognition of faith-based recovery models |
| Settlement fund oversight | 6/10 | Supports; wants faith-based programs eligible for funding | Inclusion of faith-based treatment in approved uses |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 3/10 | Opposes harm reduction provisions; supports accountability | SCS and SSP funding morally unacceptable; insufficient recognition of faith-based approaches |
| MAT Access Act | 5/10 | Mixed; supports treatment access but prefers abstinence models | Medication-based treatment seen as incomplete without spiritual recovery |
| Naloxone for All Act | 7/10 | Supports as pro-life measure | Aligned with sanctity of life principle |

#### Alternative Proposals

- Federal support for faith-based recovery programs (grants, facilities, training)
- Emphasis on family strengthening and youth prevention programs
- Compassionate alternative sentencing focused on spiritual transformation
- Community-based support through churches and religious organizations
- Abstinence-based treatment as primary approach with medication as transitional support

#### Coalition Potential

- **Natural allies:** Conservative (on values-based approach, enforcement), Populist (on community protection)
- **Potential bridges:** Centrist (on treatment funding), Liberal (on compassion framing)
- **Unlikely partners:** Progressive (on harm reduction), Libertarian (on individual choice in drug use), Democratic Socialist (on secular approach)

---

### Democratic Socialist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | Genuine commitment to universal public services and corporate accountability; positions align with broader platform |
| Principle consistency | Consistently applies public goods and anti-corporate framework; treats opioid crisis as failure of capitalism |
| Goalpost stability | Stable; positions integrated into comprehensive social democratic platform |
| Zero-sum behavior | Low; seeks transformative solutions rather than incremental gains |

**Justification:** Democratic socialists have been consistent in framing the opioid crisis as a consequence of pharmaceutical industry profit-seeking within a capitalist healthcare system. Positions are coherent and stable within the broader platform of universal public services and corporate accountability.

**Evidence for assessment:**

- DSA health justice platform includes comprehensive addiction treatment
- Medicare for All proposals include universal substance use disorder coverage
- Consistent advocacy for pharmaceutical industry nationalization or heavy regulation
- Support for comprehensive harm reduction as public health measure

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | Strong agreement with crisis severity and systemic analysis |
| Root Cause Agreement | 9/10 | Strong agreement on corporate greed, regulatory capture, and economic despair; adds capitalist system analysis |

**Source references:**

- DSA Medicare for All platform
- Jacobin magazine opioid crisis analysis
- Congressional Progressive Caucus drug policy positions
- Public Citizen pharmaceutical industry analysis

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| MAT expansion | 9/10 | Strongly supports within universal healthcare | Prefers public delivery system |
| Universal naloxone | 9/10 | Strongly supports; advocates public manufacture | Opposes pharmaceutical profit from crisis response |
| Harm reduction | 10/10 | Fully supports comprehensive harm reduction | Views harm reduction as public health right |
| Industry accountability | 10/10 | Supports maximum accountability including criminal prosecution and nationalization | Settlements insufficient; systemic restructuring needed |
| Prevention | 9/10 | Supports with emphasis on economic justice | Prevention requires addressing poverty, inequality, and exploitation |
| Enforcement | 2/10 | Opposes drug war; supports full decriminalization | Enforcement perpetuates racial and class oppression |
| Workforce development | 9/10 | Supports with public sector emphasis and living wages | Workers should be well-compensated public employees |
| Settlement fund oversight | 9/10 | Supports community-controlled funds with worker representation | Democratic control over resources |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| OCRAA | 7/10 | Supports but wants stronger provisions | Appropriations insufficient; accountability too weak; need full decriminalization |
| MAT Access Act | 8/10 | Strongly supports | Should be part of universal healthcare |
| Naloxone for All Act | 8/10 | Supports; wants public manufacturing | Prefers government production to pharmaceutical pricing negotiations |

#### Alternative Proposals

- Medicare for All with comprehensive addiction treatment coverage
- Public manufacture of naloxone, buprenorphine, and methadone
- Full drug decriminalization
- Federal jobs guarantee for affected communities
- Pharmaceutical industry nationalization or utility-style regulation
- Reparations for communities devastated by the crisis

#### Coalition Potential

- **Natural allies:** Progressive (on systemic reform, accountability), Liberal (on treatment, public investment)
- **Potential bridges:** Populist (on anti-corporate sentiment)
- **Unlikely partners:** Conservative (on government role), Libertarian (on regulation), Constitutionalist (on federal authority)

---

## Summary Tables

### Master Comparison

| Perspective | Consistency | Current State | Root Causes | Solutions Avg | Legislation Avg |
|-------------|-------------|---------------|-------------|---------------|-----------------|
| Conservative | 3/5 | 7/10 | 5/10 | 5.9/10 | 5.0/10 |
| Liberal | 4/5 | 9/10 | 8/10 | 8.1/10 | 8.7/10 |
| Progressive | 4/5 | 9/10 | 9/10 | 8.3/10 | 7.7/10 |
| Libertarian | 4/5 | 7/10 | 5/10 | 4.4/10 | 3.7/10 |
| Constitutionalist | 4/5 | 6/10 | 5/10 | 4.4/10 | 3.3/10 |
| Populist | 3/5 | 7/10 | 6/10 | 6.3/10 | 5.7/10 |
| Centrist | 4/5 | 9/10 | 8/10 | 7.6/10 | 7.3/10 |
| Religious Right | 3/5 | 7/10 | 5/10 | 5.9/10 | 5.0/10 |
| Democratic Socialist | 4/5 | 9/10 | 9/10 | 8.4/10 | 7.7/10 |

### Solution Support Matrix

| Solution | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|----------|-----|-----|------|------|-------|-----|------|------|--------|
| MAT expansion | 6 | 9 | 9 | 7 | 5 | 6 | 9 | 5 | 9 |
| Universal naloxone | 7 | 9 | 9 | 6 | 5 | 7 | 9 | 7 | 9 |
| Harm reduction (SSPs/SCS) | 3 | 8 | 10 | 7 | 4 | 3 | 6 | 2 | 10 |
| Industry accountability | 4 | 9 | 10 | 4 | 5 | 9 | 7 | 6 | 10 |
| Prevention | 7 | 8 | 9 | 5 | 5 | 7 | 8 | 9 | 9 |
| Enforcement/border | 8 | 5 | 3 | 2 | 4 | 9 | 6 | 7 | 2 |
| Workforce development | 6 | 8 | 8 | 4 | 4 | 6 | 8 | 6 | 9 |
| Settlement oversight | 6 | 9 | 9 | 3 | 3 | 7 | 8 | 6 | 9 |

### Legislation Support Matrix

| Bill | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|------|-----|-----|------|------|-------|-----|------|------|--------|
| OCRAA | 4 | 8 | 7 | 3 | 3 | 5 | 6 | 3 | 7 |
| MAT Access Act | 5 | 9 | 8 | 5 | 4 | 5 | 8 | 5 | 8 |
| Naloxone for All Act | 6 | 9 | 8 | 3 | 3 | 7 | 8 | 7 | 8 |

### Engagement Consistency Distribution

| Level | Count | Perspectives |
|-------|-------|--------------|
| 5 - Highly Consistent | 0 | None |
| 4 - Mostly Consistent | 6 | Liberal, Progressive, Libertarian, Constitutionalist, Centrist, Democratic Socialist |
| 3 - Mixed Consistency | 3 | Conservative, Populist, Religious Right |
| 2 - Low Consistency | 0 | None |
| 1 - Unpredictable | 0 | None |

**High Consistency Majority:** 6/9 perspectives rated 4 or above

### Common Ground Synthesis

| Reform Category | Broad Support (5+) | Narrow Support (3-4) | Structural Opposition |
|-----------------|-------------------|---------------------|----------------------|
| MAT expansion | Liberal, Progressive, Libertarian, Centrist, Democratic Socialist, Conservative, Populist | Constitutionalist, Religious Right | None |
| Universal naloxone | All 9 perspectives (5+) | None | None |
| Comprehensive harm reduction | Liberal, Progressive, Libertarian, Centrist, Democratic Socialist | Conservative, Constitutionalist, Populist | Religious Right |
| Industry accountability | Liberal, Progressive, Populist, Centrist, Democratic Socialist, Religious Right | Conservative, Constitutionalist, Libertarian | None |
| Prevention programs | All 9 perspectives (5+) | None | None |
| Border enforcement focus | Conservative, Populist, Religious Right | Centrist, Constitutionalist | Liberal, Progressive, Libertarian, Democratic Socialist |

**Key insight:** Naloxone expansion and prevention programs have universal support across all perspectives. MAT expansion has near-universal support. The deepest divisions are on harm reduction (SSPs/SCS) and enforcement vs. public health framing. Industry accountability has broad support but with varying intensity. These patterns suggest that a sequenced strategy--leading with universal-support items, then building toward more contested reforms--is the most viable path.

---

## Compromise Proposals

### Compromise 1: Bipartisan Treatment and Naloxone Expansion

**Bridges:** Conservative + Liberal + Centrist + Populist + Religious Right

**Core Agreement:** All perspectives agree that treatment access should be expanded and naloxone should be widely available. These are the highest-consensus items across the political spectrum.

**Policy Description:**

Combine the MAT Access Act and Naloxone for All Act into a single bipartisan package, removing the most politically contested provisions (price controls, compulsory licensing, SCS authorization) and adding provisions to satisfy conservative and religious right concerns (faith-based program eligibility, abstinence option preservation, border enforcement funding).

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | Expands treatment without mandating harm reduction; respects market mechanisms; includes enforcement provisions |
| Liberal | Dramatically expands MAT access and naloxone availability; insurance parity enforcement |
| Centrist | Evidence-based, bipartisan, politically feasible |
| Populist | Treatment for working-class communities; accountability for pharma; border enforcement |
| Religious Right | Faith-based programs eligible; abstinence pathways preserved; life-saving naloxone aligns with pro-life values |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | Accept expanded federal spending on treatment; accept methadone reform |
| Liberal | Defer SCS authorization; accept weaker price controls; include enforcement provisions |
| Populist | Accept medication-based treatment alongside abstinence approaches |
| Religious Right | Accept MAT as legitimate treatment alongside faith-based recovery |

**Viability Assessment:**

- **Coalition Size:** 7/9 perspectives (all except Libertarian and Constitutionalist on spending concerns, though they may support deregulatory elements)
- **High Consistency Ratio:** 4/5 core coalition members rated 4+ consistency
- **Durability:** High; builds on SUPPORT Act precedent and bipartisan opioid caucus framework
- **Implementation Path:** Could be introduced as bipartisan legislation through Senate Health Committee and House Energy and Commerce Committee

---

### Compromise 2: Settlement Fund Accountability and Transparency

**Bridges:** Liberal + Progressive + Populist + Centrist + Democratic Socialist

**Core Agreement:** Most perspectives agree that opioid settlement funds should be directed to evidence-based purposes and not diverted to general government budgets. The tobacco settlement experience is a shared cautionary tale.

**Policy Description:**

A standalone settlement fund oversight bill establishing federal transparency requirements and evidence-based allocation standards, using conditional spending (federal funding incentives) rather than direct mandates. States that establish independent oversight boards and direct 85%+ of funds to approved opioid abatement uses receive priority for federal opioid grants.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Liberal | Evidence-based allocation protects funds from diversion |
| Progressive | Community representation on oversight boards; funds directed to treatment and harm reduction |
| Populist | Funds reach affected working-class communities rather than government bureaucrats |
| Centrist | Transparent, accountable, evidence-based--the centrist ideal |
| Democratic Socialist | Democratic community control over resources; public accountability |
| Conservative | Conditional incentives rather than mandates; respects state flexibility within framework |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Liberal | Accept incentive-based approach rather than mandates |
| Progressive | Accept incremental oversight rather than full community control |
| Populist | Accept professional oversight board rather than purely community-controlled process |
| Conservative | Accept federal involvement in state fund management (even if incentive-based) |
| Constitutionalist | May grudgingly accept conditional spending approach |

**Viability Assessment:**

- **Coalition Size:** 6/9 perspectives (potentially 7 with modified Conservative support)
- **High Consistency Ratio:** 5/6 core coalition members rated 4+ consistency
- **Durability:** High; settlement fund accountability has broad public support and limited organized opposition
- **Implementation Path:** Could be introduced as standalone legislation or amendment to appropriations; settlement fund allocation is time-sensitive as distributions are already beginning

---

### Compromise 3: Community Prevention and Family Support

**Bridges:** Conservative + Religious Right + Centrist + Liberal + Populist

**Core Agreement:** Prevention is the only reform category with universal or near-universal support across all perspectives. A prevention-focused package that emphasizes families, communities, and youth can bridge the deepest ideological divides.

**Policy Description:**

A comprehensive prevention package combining evidence-based school programs, community coalitions, family support services, and prescribing stewardship. Explicitly includes faith-based and community organizations as eligible providers. Includes economic development provisions for communities devastated by the crisis, connecting prevention to economic opportunity.

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | Family-focused, community-based, includes faith organizations |
| Religious Right | Faith-based programs eligible; family strengthening emphasis; youth protection |
| Centrist | Evidence-based programs with measurable outcomes |
| Liberal | Comprehensive prevention including social determinants; equity provisions |
| Populist | Economic development for affected working-class communities; community empowerment |
| Progressive | Social determinants of health approach; community investment |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | Accept federal spending on prevention programs |
| Religious Right | Accept evidence-based program requirements that may not include all faith-based approaches |
| Liberal | Accept faith-based program inclusion; defer harm reduction framing |
| Progressive | Accept incremental rather than transformative economic reform |
| Populist | Accept evidence requirements for community programs |

**Viability Assessment:**

- **Coalition Size:** 8/9 perspectives (Libertarian may support deregulatory elements)
- **High Consistency Ratio:** 4/5 core coalition members rated 4+ consistency
- **Durability:** Very high; prevention and family support have the broadest political base
- **Implementation Path:** Most politically feasible of the three compromises; could be attached to education or community development legislation

---

## Strategic Implications

### Most Viable Coalition

The broadest viable coalition for opioid reform includes Liberal, Centrist, Conservative (on treatment), Populist (on accountability), and Religious Right (on prevention and naloxone). This coalition built the SUPPORT Act in 2018 and can be reconstituted for incremental expansion. Progressive and Democratic Socialist perspectives can be included on specific provisions (accountability, treatment expansion) even when they seek more comprehensive reform.

### Key Obstacles

1. **Harm reduction division**: SSPs and SCS remain the most divisive reform area, splitting the coalition between Conservative/Religious Right/Populist and Liberal/Progressive/Democratic Socialist. Leading with harm reduction risks fracturing the broader coalition
2. **Federal spending resistance**: Constitutionalist and Libertarian perspectives oppose the scale of federal investment needed, and fiscal conservatives within the Conservative perspective create additional friction
3. **Enforcement framing**: The framing of enforcement (border security vs. public health) divides the coalition along predictable lines that mirror broader immigration and criminal justice debates
4. **Industry accountability scope**: While most perspectives support some accountability, the range spans from "existing settlements are sufficient" (Conservative) to "nationalize the industry" (Democratic Socialist)

### Low Consistency Partners

Conservative (3/5), Populist (3/5), and Religious Right (3/5) are the least consistent partners. For each:
- **Conservative**: Address concerns by framing treatment as fiscally responsible (cost-benefit evidence) and providing state flexibility
- **Populist**: Channel anti-elite energy toward pharmaceutical accountability and community investment
- **Religious Right**: Lead with pro-life naloxone framing and family prevention; defer harm reduction

### Recommended Approach

A sequenced, three-track strategy:

1. **Track 1 (immediate, broad coalition)**: Bipartisan treatment and naloxone expansion (Compromise 1), which has the broadest support and saves the most lives in the shortest timeframe
2. **Track 2 (near-term, moderate coalition)**: Settlement fund accountability (Compromise 2), which is time-sensitive and has strong public support
3. **Track 3 (medium-term, evolving coalition)**: Expand toward harm reduction and systemic reform as evidence accumulates, public opinion shifts, and the treatment infrastructure demonstrates results

This approach maximizes lives saved in the near term while building toward more comprehensive reform over time.

---

## Document Navigation

- Previous: [Legislation](11-legislation.md)
- Up: [Overview](01-overview.md)
